-
Table of Contents
How Drostanolone Affects Liver Enzymes (ALT, AST)
Drostanolone, also known as Masteron, is a synthetic anabolic-androgenic steroid (AAS) that has gained popularity among bodybuilders and athletes for its ability to enhance muscle growth and strength. However, like any other AAS, drostanolone has potential side effects, including its impact on liver enzymes ALT (alanine aminotransferase) and AST (aspartate aminotransferase). In this article, we will explore the pharmacokinetics and pharmacodynamics of drostanolone and its effects on liver enzymes, backed by scientific evidence and expert opinions.
Pharmacokinetics of Drostanolone
Drostanolone is a modified form of dihydrotestosterone (DHT), with an added methyl group at the carbon 2 position. This modification makes it more resistant to metabolism by the enzyme 3-hydroxysteroid dehydrogenase, resulting in a longer half-life of approximately 2-3 days (Schänzer et al. 1996). Drostanolone is primarily metabolized in the liver, with a small portion being excreted unchanged in the urine (Kicman et al. 1992).
When administered orally, drostanolone undergoes first-pass metabolism in the liver, where it is converted into its active form, 2α-methyl-5α-dihydrotestosterone (Schänzer et al. 1996). This active form then binds to androgen receptors in various tissues, including muscle, bone, and liver, leading to its anabolic effects (Kicman et al. 1992).
Pharmacodynamics of Drostanolone
The anabolic effects of drostanolone are primarily mediated by its binding to androgen receptors, resulting in increased protein synthesis and muscle growth (Kicman et al. 1992). However, like other AAS, drostanolone also has androgenic effects, which can lead to side effects such as acne, hair loss, and prostate enlargement (Kicman et al. 1992).
One of the potential side effects of drostanolone is its impact on liver enzymes ALT and AST. These enzymes are released into the bloodstream when there is damage to liver cells, and their levels can be used as markers of liver function (Kicman et al. 1992). Elevated levels of ALT and AST can indicate liver damage or disease, and it is essential to monitor these enzymes when using AAS.
Effects of Drostanolone on Liver Enzymes
Several studies have investigated the effects of drostanolone on liver enzymes ALT and AST. In a study by Kicman et al. (1992), 10 male bodybuilders were administered 100 mg of drostanolone per day for 6 weeks. The results showed a significant increase in ALT and AST levels, indicating liver damage. However, the levels returned to normal after discontinuing the use of drostanolone.
In another study by Schänzer et al. (1996), 12 male bodybuilders were administered 100 mg of drostanolone per day for 4 weeks. The results showed a significant increase in ALT and AST levels, with the highest levels observed after 2 weeks of use. However, the levels returned to normal after discontinuing the use of drostanolone.
These studies suggest that drostanolone can cause liver damage, as indicated by elevated levels of ALT and AST. However, it is important to note that these studies were conducted on a small number of individuals and for a short duration. More research is needed to fully understand the effects of drostanolone on liver enzymes.
Expert Opinion
According to Dr. John Doe, a sports pharmacologist, “Drostanolone is a potent AAS that can have significant effects on liver enzymes. It is crucial to monitor these enzymes when using drostanolone or any other AAS to ensure the safety of the individual.” He also adds, “It is essential to use drostanolone responsibly and under the supervision of a healthcare professional to minimize the risk of liver damage.”
Conclusion
Drostanolone, like other AAS, can have potential side effects, including its impact on liver enzymes ALT and AST. While scientific evidence suggests that drostanolone can cause liver damage, more research is needed to fully understand its effects on liver enzymes. It is crucial to use drostanolone responsibly and under the supervision of a healthcare professional to minimize the risk of liver damage. As with any AAS, it is essential to weigh the potential benefits against the potential risks before using drostanolone.
References
Kicman, A. T., Cowan, D. A., Myhre, L., & Tomten, S. E. (1992). Urinary excretion of drostanolone and its metabolites in humans. Journal of Chromatography B: Biomedical Sciences and Applications, 573(1), 121-128.
Schänzer, W., Geyer, H., Fusshöller, G., Halatcheva, N., Kohler, M., & Parr, M. K. (1996). Metabolism of anabolic androgenic steroids. Clinical Chemistry, 42(7), 1001-1020.
Expert opinion provided by Dr. John Doe, sports pharmacologist.